Nordic Nanovector: Results From Preclinical Studies Of Betalutin In Combination With Rituximab In Non-Hodgkin Lymphoma Model To Be Presented At American Society of Hematology
11/3/2016 9:32:50 AM
Oslo, Norway, 3 November 2016
Nordic Nanovector ASA (OSE: NANO) announces that a poster describing the therapeutic effect of combined treatment with Betalutin® (177Lu-satetraxetan-lilotomab) and rituximab in a preclinical model of non-Hodgkin lymphoma (NHL) (abstract 4189) will be presented at the 58th Annual American Society of Hematology (ASH) meeting (3-6 December 2016 in San Diego, CA, USA). These studies build on previously presented data showing that treatment with Betalutin® increased binding of rituximab to NHL cells and uptake of rituximab in NHL tumours. The combination treatment resulted in 90-100 % survival for 150 days after treatment, while each treatment alone gave from 10 to 40 % survival.
The ASH annual meeting is the premier event for scientific exchange in the field of hematology, attracting more than 20,000 attendees from all over the world. Typically, more than 5,000 scientific abstracts are submitted each year, and more than 3,000 abstracts are accepted for oral and poster presentations through an extensive peer review process.
Abstract title: Combination of 177lutetium-Satetraxetan-Lilotomab and Rituximab Results in Improved Therapeutic Effect in Preclinical Models of Non-Hodgkin Lymphoma
Authors: Repetto-Llamazares, AHV et al.
Session Name: 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster III
Date/Time: Monday, 5 December 2016, 6:00 PM - 8:00 PM (PST)
Location: San Diego Convention Center, Hall GH
Link to abstract: https://ash.confex.com/ash/2016/webprogram/Paper89561.html
comments powered by